Evaxion to present Phase 2 biomarker data for cancer vaccine EVX-01 at SITC 2026
EVAX•Evaxion will present Phase 2 data on its personalized cancer vaccine EVX-01 at SITC in Phoenix on November 6-7, 2026; the vaccine combined with pembrolizumab induced cancer-targeting immune responses and broader immune changes in patients with advanced melanoma.
1. Presentation planned
Evaxion will present new Phase 2 data on its personalized cancer vaccine EVX-01 at SITC in Phoenix on November 6-7, 2026. The vaccine, combined with pembrolizumab, induced cancer-targeting immune responses and broader immune changes in patients with advanced melanoma.
